Wednesday , April 25 2018
Home / Production Assistant, Diabetes In Control (page 9)

Production Assistant, Diabetes In Control

Insulin vs Other Treatment Options

Are you more likely to add a basal insulin to the treatment plan for a patient with type 2 on two oral meds with an A1c of 8% for 5 months, BMI of 30, or add another medication besides insulin? More likely to add insulin More likely to add another med besides insulin Follow the link to share your opinion.

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #114: Diabetes and Sleep Apnea Part 4

OSA and glucose metabolism: OSA and dysglycemia have similar risk factors (namely obesity) and hence it is not surprising that these conditions co-exist. However, not all obese patients have both conditions and many patients have one and not the other. Hence, understanding this association and the mechanisms that underpin this relationship is important to understand the pathogenesis of OSA and T2DM. There are many studies that have examined the association between snoring, as a surrogate marker of OSA, and different aspects of glucose metabolism; here, however, we will mainly focus on studies that validated the presence and severity of OSA using more accurate methods.

Read More »

The Coming Debate on Closed-Loop Insulin Delivery Systems

Guest Post by David Kliff, Editor, Diabetic Investor

As I left Vienna after attending the 11th International Conference on Advanced Technologies & Treatments for Diabetes, my thoughts turned to what does this all mean, what was the most significant takeaway? By far the most significant development coming out of ATTD is the long quest to have a REAL closed-loop insulin delivery system is no longer a pipe dream. This is going to happen and for once I believe it will happen in my lifetime. It is difficult to overstate the power of the data I witnessed. The reality here is that some very smart people have come a very long way.

Read More »

Reducing Heart Risk

According to a recent study, which one of the following diabetes therapies carries a lower risk for adverse cardiovascular (CV) events? 1. Nonspecific, long-acting sulfonylureas (eg, glyburide and glimepiride) 2. Specific, short-acting sulfonylureas (eg, glipizide, tolbutamide) 3. CV risk does not differ between these agents Follow the link for the answer.

Read More »